Anzeige
Mehr »
Mittwoch, 25.02.2026 - Börsentäglich über 12.000 News
Von Polen bis Virginia Beach- zündet hier der nächste Smallcap-Turbo?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Investing.com

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
DiPrimoris Q4 2025 slides: record year marred by margin pressures
DiGerdau 2025 presentation: North America gains offset Brazil import surge
DiLeonardo DRS Q4 2025 slides show 8% growth, strong 2026 outlook
DiTennant Q4 2025 slides: ERP crisis drives 71% earnings miss
DiWedbush raises Kiniksa stock price target to $53 on launch outlook
DiHelix Energy Q4 2025 slides: cash surges despite revenue decline
DiHICL Infrastructure declares 2.09p third interim dividend
DiPortillo's Q4 2025 slides: earnings beat masks margin pressure
DiUBS reiterates Gap stock Buy rating on solid sales trends
DiUBS raises Axsome Therapeutics stock price target on sales force expansion
DiChewy stock gets new CFO with Amazon experience, Mizuho reiterates Outperform
DiStifel reiterates Fulcrum Therapeutics stock rating on drug data
DiUBS reiterates Buy on MBX Biosciences stock, keeps $60 target
DiUBS cuts Laureate Education stock price target on margin pressures
DiUBS raises Keysight stock price target on AI demand acceleration
DiUBS reiterates Domino's Pizza stock rating on solid US sales growth
DiGLJ Research maintains Tesla stock sell rating on Optimus risk
DiUBS reiterates Broadcom stock rating citing semiconductor valuation
DiGraham Holdings declares $1.88 quarterly dividend
DiBenchmark reiterates Taboola stock rating ahead of earnings
DiBenchmark reaffirms Starz Entertainment stock rating ahead of earnings
DiGalapagos stock rating reiterated at Market Perform by Raymond James
DiFreshpet stock price target raised to $90 by Benchmark on margins
DiBenchmark reiterates Buy on A2Z Smart Technology stock at $30
DiFulcrum Therapeutics shares fall on profit-taking, Oppenheimer says